Takeda Pharmaceuticals USA (TPUSA) and Affymax have announced supply agreement with US Renal Care for Omontys (peginesatide) injection in the US.
Under the agreement, US Renal Care will purchase Omontys for use within its organization and provides for discounts and rebates on the product, subject to certain requirements.
The US Renal Care considers initial evaluation of Omontys in selected centers and latter, based on experience, evaluate the potential to expand to additional centers. Financial terms were kept confidential.
Takeda marketing vice president Nicole Mowad-Nassar said, "As we anticipated, there is interest from some of the world's leading dialysis providers to offer a new therapeutic option for the treatment of anemia in chronic kidney disease patients on dialysis."
Omontys is the once-monthly erythropoiesis-stimulating agent for anemia available to the dialysis patient population with chronic kidney disease in the US.
Affymax chief executive officer John Orwin said the centers are demonstrating an interest in offering new therapies and showing commitment to innovation.
"We intend to support their integration efforts and believe OMONTYS will prove to be a once-monthly alternative in their centers moving forward," Orwin added.
